Pliant Therapeutics has discontinued its idiopathic pulmonary fibrosis (IPF) development program after a detailed assessment revealed an increase in adverse events in a Phase 2b/3 clinical trial of its lead candidate, bexotegrast. This setback significantly impacts efforts to address IPF with new therapeutics and signals caution for related anti-fibrotic drug development ventures.